David Black, MD
Internal Medicine · Birmingham, ALNPI 1457324352
Payments from drug & device makers
Across 241 payments — averaging $17.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$526
- Pfizer$395
- GSK$387
- Bayer$353
- Exact Sciences$302
- Novo Nordisk$282
- plus $2K from 25 others
What the payments were for
- Food & beverage$4,125100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 33 | $526 |
| Pfizer | 21 | $395 |
| GSK | 27 | $387 |
| Bayer | 22 | $353 |
| Exact Sciences | 20 | $302 |
| Novo Nordisk | 15 | $282 |
| AbbVie | 17 | $260 |
| Abbott | 13 | $259 |
| Dexcom, Inc. | 11 | $214 |
| Amgen | 9 | $209 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $169 |
| Amarin Pharma, Inc. | 8 | $133 |
| Boehringer Ingelheim | 7 | $116 |
| Otsuka America Pharmaceutical, Inc. | 4 | $83 |
| Johnson & Johnson | 3 | $52 |
| Impulse Dynamics (USA) Inc. | 2 | $51 |
| Phathom Pharmaceuticals, Inc. | 3 | $50 |
| AstraZeneca | 3 | $43 |
| Xeris Pharmaceuticals, Inc. | 2 | $35 |
| Novartis | 1 | $31 |
| Sumitomo Pharma America, Inc. | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $21 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $18 |
| Lundbeck LLC | 1 | $18 |
| Intra-sana Laboratories | 1 | $15 |
| IBSA Pharma Inc. | 1 | $15 |
| Tolmar, Inc. | 1 | $14 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Nabriva Therapeutics, PLC | 1 | $13 |
| Merck | 1 | $13 |
| Arbor Pharmaceuticals, Inc. | 1 | $12 |
How this compares
$4,125 in reported general payments places this provider in the 80th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 81 | $83,308 |
| EliquisApixaban | 100 | $75,766 |
| JanuviaSitagliptin Phosphate | 94 | $74,442 |
| OzempicSemaglutide | 54 | $61,316 |
| MounjaroTirzepatide | 53 | $58,308 |
| JardianceEmpagliflozin | 62 | $57,230 |
| RybelsusSemaglutide | 34 | $37,136 |
| LinzessLinaclotide | 34 | $32,817 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 28 | $25,500 |
| XareltoRivaroxaban | 12 | $18,981 |
| JanumetSitagliptin Phos/Metformin Hcl | 14 | $16,017 |
| KerendiaFinerenone | 21 | $13,576 |
| SynjardyEmpagliflozin/Metformin Hcl | 14 | $9,279 |
| SynthroidLevothyroxine Sodium | 88 | $8,876 |
| Rosuvastatin Calcium | 409 | $7,722 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| MerckJanuvia, Janumet Xr, Janumet | $13 | $115,958136 claims |
| Novo NordiskOzempic, Rybelsus | $282 | $98,45288 claims |
| AstraZenecaFarxiga | $43 | $83,30881 claims |
| PfizerEliquis | $395 | $75,766100 claims |
| Boehringer IngelheimJardiance, Synjardy | $116 | $66,50876 claims |
| Lilly USA, LLCMounjaro | $526 | $58,30853 claims |
| AbbVieLinzess, Synthroid | $260 | $41,693122 claims |
| Johnson & JohnsonXarelto | $52 | $18,98112 claims |
| BayerKerendia | $353 | $13,57621 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $387 | $12,08824 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Birmingham
- David DeatkineBirmingham$8M
- James SullivanBirmingham$6M
- Ramy TomaBirmingham$5.1M
- William KirbyBirmingham$2.3M
- Jordan VaughnBirmingham$1.6M
- Stefanie KrickBirmingham$527K
- Ryan WeldonBirmingham$458K
- Ashraf KhanBirmingham$215K
- Robert LewisBirmingham$201K
- David WynneBirmingham$180K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.